KR20200077093A - Composition for relieving and improving acute facial pain containing boswellia extract and seabuckthorn extract - Google Patents

Abstract

A composition for preventing and alleviating acute facial pain according to the present invention contains a Boswellia extract and a Hippophae Rhamnoides extract. According to the composition for preventing and alleviating acute facial pain derived from the present invention, it is possible to alleviate acute facial pain.

Description

Composition for relieving and improving acute facial pain containing boswellia extract and seabuckthorn extract

The present invention relates to a composition for preventing and improving acute facial pain, comprising a Boswellia extract and a Seabuckthorn extract, and preventing acute facial pain without side effects even when the dose and duration of administration are increased. It relates to a composition for improvement.

Acute facial pain is also referred to as acute oral facial pain or acute facial pain, and is generally temporary in the maxillofacial area such as the clause (chin joint), weak bone (chin), face (face), mouth (tongue or cheek), head, neck and shoulders. Alternatively, it refers to periodic acute pain and may be distinguished from chronic pain caused by periodontal disease.

In addition, facial pain includes neuropathic pain, such as trigeminal and migraine headaches, as well as pain due to damage to the teeth, alveolar bones, oral soft tissues and temporomandibular joints. These pains are nociceptive pain, a kind of warning sensation caused by harmful stimuli that can damage or potentially damage tissues, and IL-1β (interleukin 1) that is activated and secreted from damaged tissues and surrounding tissues. It can be distinguished as inflammatory pain caused by the inflammatory mediators acting on the harmful receptors, and neuropathic pain that persists even in non-toxic stimuli due to damage to the peripheral and central nerves.

Inflammatory pain prevents further damage by limiting the movement of the pain area and disappears after a certain period of time, but it seems to be important to control inflammatory pain because it may develop into neuropathic pain as it progresses in the direction of harm to ‹š.

The acute facial pain may occur during dental treatment, scaling, or other dental hygiene procedures, and sometimes refers to regular or irregular sudden pain without a specific cause.

The acute facial pain may be specifically divided into afferent blockage pain syndrome, trigeminal neuralgia, mouthburn syndrome, and tension headache.

The centripetal blockage pain syndrome The centripetal blockage pain syndrome refers to a condition in which sensitization occurs when there is damage or inflammation of the sensory nerve, and pain persists even when there is no cause of external pain. In this case, sudden pain may occur due to dental treatment, scaling, or other mild stimulation, and small pain may be felt greatly. Sometimes, in addition to pain, a strange sensation may be felt. Most of the cases of burning, tingling, tingling, or dull pain in the adjacent area after treatment of a tooth or removal of a tooth from a dentist or after treatment of a gum are often associated with afferent pain syndrome. In addition, the acute facial pain associated with the afferent pain syndrome is not treated well with general pain relievers, and many antidepressants and anticonvulsants are used. Recently, capsaicin cream or gabapentin may be used.

In addition, the trigeminal neuralgia causes shocking pains such as sudden electricity in the face or mouth during everyday life, and does not move. After that moment, the pain immediately disappears, but if you touch any part of the face or mouth, it becomes electricity again. It is characterized by recurring pain that seems to cause pain. Most of the patients appear in middle-aged or older, and the pain appears only on either side of the left or right side of the face or chin. It does not appear on both sides. These trigeminal neuralgia rarely have a therapeutic effect as a general pain reliever, and drugs such as carbamazepine, bacrofen, and amitriptyline should be used alone or in combination. The drug must be used for a long time, so you need to be aware of side effects and undergo regular blood tests. If medication is ineffective, surgery may be considered.

In addition, the burning sensation syndrome refers to feeling of pain in the mucous region of the tongue or mouth without any specific cause, and is mainly seen in postmenopausal women. Patients with burning sensation syndrome often complain of burning or tingling or soreness in the 2/3 area of the front of the tongue, anterior of the palate, and lips, but sometimes the symptoms include dry mouth and taste disorders. The exact cause of the burning sensation syndrome has not been identified, and it is assumed that only hormonal changes, psychological factors, and degenerative changes in the taste nerve are involved. In general, it is possible to relieve symptoms by administering amitriptyline and clonazepam or applying capsaicin cream, but it is not easy to cure. In the case of oral candidiasis, antifungal agents such as nistatin or ketoconazole should be used, and if dry mouth feels, pilocarpine or artificial saliva is prescribed.

Furthermore, the tension headache is the highest incidence among headaches and appears as a feeling of head tightening, heavy or throbbing. It usually feels pain on both sides of the head and is worse in the afternoon than in the morning. The intensity of the pain is not constant, but it does not appear extreme. Stress or muscle tension are known to be the main causes of tension headaches, but other causes are also involved. Drug therapy is mainly used for the treatment of such tension headaches, but a better therapeutic effect can be obtained when both behavioral therapy and physical therapy are performed. Recently, Botox injection is recommended as a treatment for tension headaches.

Therefore, the acute facial pain in the present invention includes acute facial pain caused by afferent blockage pain syndrome, trigeminal neuralgia, oral burning syndrome, and tension headache, and is defined as including sudden and temporary accompanying oral facial pain symptoms. .

The acute facial pain is generally a case where acute pain is not sedated even when a general pain reliever is used, and even if effective, there is a problem that the dose of the pain reliever is inevitably increased due to its insignificant degree compared to other pain. In particular, the acute facial pain occurs regularly in a regular or irregular pattern than when the temporary symptoms are ended, and there are many patients complaining of pain, but there is a problem that the pain reliever specialized in this is very limited.

Therefore, while using the natural composition to achieve a relief effect for the above-described acute facial pain, it is necessary to prevent the problem of side effects according to the dosage and duration of use by using the natural composition.

Preferably, the acute facial pain referred to in the present invention may be an acute temporomandibular joint pain.

In this regard, the prior art is only intended to produce a general analgesic effect, and the present invention is not intended for acute facial pain (acute oral facial pain) that is the subject of the present invention, so there is no analgesic effect or dose for acute facial pain This has the problem that it should be quite a lot.

In addition, the prior art for facial pain also has a large number of mechanisms for chronic pain, and such a mechanism is used in acute facial pain in the present invention, which has a problem that it is difficult to produce an effect. Furthermore, the use of natural products related to acute facial pain is difficult to find, so the development is minimal.

A method for confirming whether the natural product can effectively control acute facial pain is a formalin test, which is one of the widely used methods among inflammatory pain models. When formalin is injected into the rat's soles, lips, temporomandibular joints, or subcutaneous faces of the rats, it is characterized by an inflammatory reaction immediately after injection and characteristic abnormal pain response caused by tissue damage. At this time, the number or time of scratching, rubbing or licking the injection site Is considered as an indicator of pain behavioral response.

After the formalin injection, the reaction that lasts for 0 to 10 minutes due to malignant sensitization by harmful stimulation and then disappears is called the first pain action response (first phase), and then continues for 11 to 45 minutes by central sensation despite the disappearance of harmful stimulation The response is called the secondary pain behavioral response (second phase). At this time, the primary pain response is considered peripheral sensitization, and the secondary behavior response can be classified as central sensitization.

The peripheral sensitization is caused by damage to tissues, while stimulating harmful receptors, substances P (substance P), histamine (histamine), Bradykinin (bradykinin), and other pain-causing substances show synergy with each other, afferent Ad, C It is a phenomenon in which pain is enhanced by lowering the threshold of the nociceptor at the end of the fiber and being strongly activated even with small stimuli.

On the other hand, the central sensitization excitability of wide-dynamic range neurons or nociceptive neurons in the spinal cord root muscle is high when high-frequency stimulation through C fibers and low-frequency stimulation through Ad fibers persist. As an increasing phenomenon, the N-methyl-D-aspartate (NMDA) receptor is activated after synapse due to the continuous secretion of glutamate, thereby causing a central sensitization as Ca2+ introduced into the cell increases.

In order to control pain in the face, various synthetic chemicals such as acetaminophen, muscle relaxants, antidepressants, nonsteroidal anti-inflammatory drugs, and opioid drugs are prescribed in clinical practice, but some dependence, tolerance, constipation, nausea, and vomiting As it causes side effects, such as recent research, there is a growing interest in pain control drugs derived from natural products with relatively few side effects.

(Patent Document 1) KR 10-2003-0040201 A1

An object of the present invention is to provide a composition for preventing and improving acute facial pain, comprising Boswellia extract and Sanja tree extract.

Another object of the present invention is to provide a composition for preventing and improving acute facial pain derived from natural products capable of alleviating acute facial pain.

Another object of the present invention is to provide a composition for preventing and improving acute facial pain comprising an active ingredient having a problem of side effects while having an effective relief effect on acute facial pain using Boswellia extract and Sanja tree extract. Is to do.

Another object of the present invention is to provide a composition for preventing and improving acute facial pain that can be used periodically or for a long period of time for irregular acute facial pain.

In order to achieve the above object, the composition for preventing and improving acute facial pain according to an embodiment of the present invention is to include Boswellia extract and Seabuckthorn extract.

The extract of the Sanja tree includes an extract selected from the group consisting of a mountain tree trunk, a mountain tree fruit, a mountain tree leaf, a mountain tree root, and a mixture thereof.

The acute facial pain is selected from the group consisting of afferent blockage pain syndrome, trigeminal neuralgia, mouthburn syndrome, tension headache and acute temporomandibular joint pain.

Functional food according to another embodiment of the present invention may include a composition for preventing and improving the acute facial pain.

The external preparation for skin according to another embodiment of the present invention may include the composition for preventing and improving the acute facial pain.

The pharmaceutical product according to another embodiment of the present invention may include a composition for preventing and improving the acute facial pain.

Hereinafter, the present invention will be described in more detail.

As used herein, the term'extract' has a meaning commonly used as a crude extract in the art as described above, but broadly also includes a fraction in which an extract is additionally fractionated. That is, the extract includes not only those obtained using the above-described extraction solvent, but also those obtained by additionally applying a purification process. For example, a fraction obtained by passing the extract through an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. The fraction obtained through the purification method is also included in the extract of the present invention.

The extract used in the present invention may be prepared in powder form by additional processes such as distillation under reduced pressure and freeze drying or spray drying.

The term'comprising as an active ingredient' in the present specification means to include an amount sufficient to achieve the efficacy or activity of the extract according to the present invention. The present invention is a composition extracted from a natural plant material, and even when administered in excess, there is no side effect on the human body, so the upper limit of the amount of the extract contained in the composition of the present invention can be carried out by a person skilled in the art within an appropriate range.

The term'acute facial pain' referred to in the present invention is also referred to as acute oral facial pain or acute facial pain, and is generally a temporomandibular joint (jaw joint), jaw bone (chin), face (face), mouth (tongue or cheek), head, neck and shoulder, etc. It refers to temporary or periodic acute pain in the maxillofacial area of the eye, and can be distinguished from chronic pain caused by periodontal disease. It can occur during dental treatment, scaling, or other dental hygiene procedures. Refers to pain.

The acute facial pain is distinguished from chronic pain, and it has a special point in that it is not effective for the acute facial pain or there is a problem of overdose as a general analgesic or anti-inflammatory analgesic.

The composition for preventing or improving acute facial pain according to an embodiment of the present invention is to include a Boswellia extract and a Seabuckthorn extract.

Boswellia is a plant belonging to the Bruseraceae family, and comes from the Boswellia serrate tree. It is mainly used for medicinal use of resin obtained from stems or branches of Indian frankincense. In recent 20-30 years, there have been increasing cases of taking preparations containing Indian frankincense resin or other frankincense plants, and in 2002, the European Medicines Agency used'orphan drugs' for the treatment of Peritumoral Brain Oedema. '. Boswellia's typical pharmacological effects include anti-viral action, activity on the immune system, inflammatory bowel disease, joint disease, anti-asthma, and anti-cancer action. In addition, in Donguibogam, frankincense is introduced as a medicine to treat skin diseases, so it can be seen that it is widely used regardless of East and West. However, the results of pain-related research have been very scarce, and the effect on the occurrence and prevention of facial pain has hardly been proven.

When the boswellia extract is used, it is specialized in acute facial pain, and can effectively suppress or alleviate the acute facial pain.

The composition for preventing and improving acute facial pain is characterized by further comprising a extract of Boewellia (Seabuckthorn) in addition to Boswellia extract.

In the present invention, the mountain tree (Seabuckthorn) is rich in vitamins and is also called a vitamin tree. This pointy plant with bright orange fruits is native to North Asia and Europe and is one of the first plants to settle on the Scandinavian peninsula after the Ice Age. This cold-tolerant and vigorous tree is a pioneering spirit and grows well in extreme climates in addition to sandy areas and coastal areas. The mountain tree is resistant to cold, covered with long thorns, and this sweet and sour fruit is used as a special delicacy in Scandinavia. Typical ingredients include omega-3/6/9 fatty acids of vitamins A, B1, B6, C, and E, but contain folic acid, potassium, and various minerals.

The extract of the mountain tree includes the extract of the mountain tree extract selected from the group consisting of a mountain tree trunk, a mountain tree fruit, a mountain tree leaf, a mountain tree root, and a mixture thereof. Preferably, an extract can be obtained and used from a mixture of a mountain tree trunk and a mountain tree root.

The Sanja tree has a variety of bioactive substances, and if you look at the area, the fruits are rich in fatty acids, such as proteins such as globulin and albumin, and fatty acids such as linoleic acids and linolenic acids. have. It is known that leaf and seed extracts are rich in antioxidant bioactive substances such as polyphenolics, tocopherols, carotenoids, and flavonoids. In particular, the leaves contain physiologically active substances such as quercetin, galic acid, and tannin, which are effective in treating skin diseases, wounds, and inflammation, and protecting cells, anti-aging, antioxidant, and anti-cancer. Research results have been reported. However, research results on the effect of reducing acute facial pain are very lacking, and particularly, the material of each part of the extract of Sanja tree has little proven in preventing acute facial pain.

When using the material of each part of the extract of the mountain tree, the acute facial pain can be more effectively alleviated by the mixed synergistic effect, thereby increasing the soothing effect of the pain in a smaller dose.

When the composition for preventing and improving the acute facial pain is used by mixing the Boswellia extract and the Sanja tree extract, the acute facial pain is prevented and prevented due to the complex action between the components according to the mixed use of the Boswellia extract and the Sanja tree extract. It can show an excellent effect on improvement.

However, compared to the case where only Boswellia extract and Sanja tree extract are used, when a natural extract is additionally used, the effect of preventing and improving acute facial pain is further increased by a complex action between natural extracts.

Preferably, the natural extract may further include an extract selected from the group consisting of Gavinja extract, Eumjigye extract, Sambaekcho extract and mixtures thereof.

The Gaebija (Cephalotaxus koreana Nakai) is an evergreen tree growing in a valley or in a forest, reaching a height of 3 m. The leaves are linear, arranged in two rows, the ends are sharply sharp, the front is green, and the stem is clear. Flowers bloom in April in Igahwa, male flowers are flat, and two female flowers run in one place. Fruits are round, ripened in red in August-September of next year, seeds are long oval, brown.

The Eumjigye is a perennial herb that grows in a sunny forest or meadow with sceptridium ternatum (Thunb.) Lyon. The thick fleshy roots spread all over the place. The leaf is divided into two, and it is composed of a nutritive lobe and a true lobe, and the lobe has a long petiole, split into three, and has jagged edges. The spore lobe is longer than the broad lobe and the upper part is split long, and the spore sac hangs on the branch.

The three hundred seconds (Saururus chinensis (Lour.) Baill.) is a perennial plant growing in wetlands, 50 to 100 cm in height, and white root. The leaves are coarse, pointed at the end, the bottom is heart-shaped, and the edges are flat. Flowers are benign, bloom white in June-August, and inflorescences cope with leaves. Fruits are round and consist of 3 to 5 threads, with 1 seed in each thread.

The composition for preventing and improving acute facial pain is used in addition to the boswellia extract and the Sanja tree extract, further comprising natural extracts selected from the group consisting of Gaejajaja extract, Eumji cigarette extract, Sambaekcho extract and mixtures thereof In the case, it is possible to relieve and soothe acute facial pain by specializing in the acute facial pain.

On the other hand, Boswellia extract and Sanja tree extract, even when used alone, have excellent effect of suppressing acute facial pain, but as described above, a group consisting of Gaeja biloba extract, Eumji cigarette extract, Sambaekcho extract and mixtures thereof When it further comprises a natural extract selected from, the synergistic effect between the constituent components makes the inhibitory effect on acute facial pain significantly superior. Therefore, even a smaller amount can have a high inhibitory effect against acute facial pain.

Specifically, in order to prepare Boswellia extract and Sanja tree extract, crushing natural products; Leaching the pulverized material using an organic solvent; Drying the sample after leaching; Re-leaching the dried sample using an organic solvent; Drying the sample after leaching; Leaching with water; And comprising the step of leaching, it is possible to obtain a natural extract.

The method may further include fractionating the natural extract extracted using the organic solvent using an organic solvent.

The method for preparing the extract may be a conventional extraction method in the art, such as an ultrasonic extraction method, a leaching method, and a reflux extraction method. Specifically, the natural product from which foreign substances have been removed by washing and drying may be an extract extracted with water, an alcohol having 1 to 6 carbons or a mixed solvent thereof, or an extract extracted by sequentially applying the solvents to a sample.

The reflux extraction method is based on 100 mL of alcohol having 1 to 6 carbon atoms, 10 to 30 g of pulverized natural products, 1 to 3 hours reflux time, and 50 to 100% alcohol with 1 to 6 carbon atoms. More specifically, based on 100 mL of alcohol having 1 to 6 carbons, 10 to 20 g of pulverized natural products, 1 to 2 hours of reflux and 70 to 90% of alcohols having 1 to 4 carbons.

The leaching method is from 15 to 30° C. for 24 to 72 hours and with 50 to 100% alcohol having 1 to 6 carbon atoms. More specifically, it is with alcohol having 1 to 6 carbon atoms at 20 to 25°C, 30 to 54 hours and 70 to 80%.

The ultrasonic extraction method is for 30 to 50°C, 0.5 to 2.5 hours, and 50 to 100% of alcohol having 1 to 6 carbon atoms. Specifically, it is 40 to 50° C., for 1 to 2.5 hours and with 70 to 80% alcohol having 1 to 6 carbon atoms.

The extraction solvent may be used 2 to 50 times based on the weight of the sample, more specifically 2 to 20 times. For extraction, the sample may be left for 1 to 72 hours for leaching in the extraction solvent, and more specifically, for 24 to 48 hours.

After extraction, the extract can be fractionated by sequentially applying a new fraction solvent. The fractionation solvent used for fractionation is any one or more selected from the group consisting of water, hexane, butanol, ethylacetic acid, ethyl acetate, methylene chloride and mixtures thereof, preferably ethyl acetate or methylene chloride.

After obtaining the extract or fraction, a method such as concentration or lyophilization may be additionally used.

Preferably, the composition of the present invention, Boswellia extract 100 parts by weight, 80-120 parts by weight of the Sanja tree extract, 40-60 parts by weight of Gaeja tree extract, 40-60 parts by weight of the extract of Eumji and 40-60 parts of Sambaekcho extract It can be included in parts by weight. When used within the above range, the effect of improving acute facial pain may be increased due to the complex action between the components.

The acute facial pain may include afferent blockage pain syndrome, trigeminal neuralgia, burning mouth syndrome, tension headache, and acute temporomandibular joint pain.

Functional food according to another embodiment of the present invention may include a composition for preventing and improving the acute facial pain.

The external preparation for skin according to another embodiment of the present invention may include the composition for preventing and improving the acute facial pain.

The external preparation for skin refers to an external preparation composition used to prevent and improve acute facial pain as a pharmaceutical or quasi-drug.

The medicine according to another embodiment of the present invention may include a composition for preventing and improving the acute facial pain.

The preferred dosage of the extract of the present invention depends on the patient's condition and body weight, the degree of disease, the drug form, the route and duration of administration, but can be appropriately selected by those skilled in the art. However, for the desired effect, the extract is administered at 0.01 mg/kg to 10 g/kg per day, preferably 1 mg/kg to 1 g/kg. The administration may be administered once a day, or may be divided into several times. Therefore, the above dosage does not limit the scope of the present invention in any way.

"Health functional food" as defined herein refers to food manufactured and processed using ingredients or ingredients having useful functionality for the human body in accordance with Act 6727 on the Health Functional Food, and "functional" means It means to ingest for the purpose of obtaining useful effects for health purposes such as adjusting nutrients for structure and function or physiological action.

When the extract according to the present invention is used as a food additive, the extract may be added as it is or used with other foods or food ingredients, and may be suitably used according to a conventional method. Examples of foods to which the above substances can be added are meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other dairy products including noodles, gums, ice cream, various soups, beverages, teas, drinks, Alcoholic beverages and vitamin complexes are included, and include all healthy foods in the ordinary sense.

According to the composition for preventing and improving acute facial pain derived from the present invention, acute facial pain can be alleviated.

According to the composition for preventing and improving acute facial pain, an extract derived from a natural product can be used periodically or for a long period of time for irregular acute facial pain because it has an effective relief effect on acute facial pain and has no side effects.

1 relates to test results of a temporomandibular joint pain model of a composition according to an embodiment of the present invention.
Figure 2 relates to the test results of the temporomandibular joint pain model of the composition according to an embodiment of the present invention.
Figure 3 relates to the test results of the subcutaneous pain model of the face of the composition according to an embodiment of the present invention.
Figure 4 relates to the test results of the subcutaneous pain model of the face of the composition according to an embodiment of the present invention.

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art to which the present invention pertains can easily practice. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein.

[Production Example: Preparation of Extract]

One. Preparation of boswellia extract

The dried boswellia is crushed, and the boswellia pulverized water is extracted by hot water extraction at 100° C. for 20 hours in a volume ratio of 20 hours, followed by filtering the extract with filter paper and drying under reduced pressure to remove boswellia extract (V1 ).

2. Preparation of Sanja extract

After drying the mountain stalks and roots, and pulverizing them to prepare a pulverized product, they were mixed. The mixed Sanja tree powder was extracted with hot water at 100°C for 20 hours in a volume ratio of 4 hours, and then the extract was filtered with filter paper and dried under reduced pressure to produce a Sanja tree extract (V2).

3. Preparation of natural extracts

In the same manner as the Boswellia extract, a mountain leaf extract (V3), a Gavin extract (V4), a umbilical extract (V5), and a three hundred second extract (V6) were prepared.

3. Preparation of complex extracts

The Boswellia extract (V1), the mountain tree extract (V2), the mountain tree leaf extract (V3), the Gavinja tree extract (V4), the umbilical extract (V5) and the three hundred vinegar extract (V6) are shown in Table 1 below. It was prepared as a composition for preventing and improving acute facial pain by mixing within a weight range.

BOS1 BOS2 BOS3 BOS4 BOS5 BOS6 BOS7 V1 100 100 100 100 100 100 100 V2 100 - 100 100 100 100 100 V3 - 100 60 80 100 120 140 V4 - - 30 40 50 60 70 V5 - - 30 40 50 60 70 V6 - - 30 40 50 60 70

(Unit weight part)

[Experimental Example 1: Formalin pain model test]

One. TMJ (temporomandibular joint) model

TMJ (temporomandibular joint) model (temporomandibular joint model, Won KA, Kang YM, Lee MK, Park MK, Ju JS, Bae YC, et al. 2012; 26(2): 132-141.) was used to conduct an acute temporomandibular pain relief effect experiment on BOS1 and the results are shown in FIGS. 1 and 2 below.

When explaining a specific experimental method, the experimental animal was adapted for 10 minutes or more in an experimental plastic container before evaluating the pain response. Insulin syringe (0.25 × 8 mm) was used to inject 30 μl of 5% formalin, and it was observed to restore consciousness within a few seconds after the formalin injection.

The location of the joint cavity was inferred by palpation of the posterior lower boundary surface of the tibia and the mandibular condyle area, and the injection needle pierced the articular sac at the corresponding site and recognized the area where it touched the mandibular cavity into the joint cavity. Preliminary experiments confirmed the location of the temporomandibular joint by injecting 1% by weight of formalin and 1w% evans blue dye to separate animals. After injecting formalin, the behavioral response of rubbing or scratching the TMJ area and the facial area is regarded as a pain indicator, and cumulatively recorded for 45 minutes, 9 times at 5 minute intervals, and the 1st painful behavior response (0-10 minutes) and the 2nd painful behavior response (11 to 45 minutes).

Referring to FIGS. 1 and 2 below, in an experiment using an animal (Rat), it is a figure showing a change in pain behavior response according to BOS1 administration in an acute pain model induced with formalin administered to the temporomandibular joint. There was no significant difference between the formalin infusion group, the control group (veh + formalin infusion group) and the drug infusion group when BOS1 was administered, but in the secondary pain behavior response, the drug infusion group (Bos1 15 mg) compared to the formalin infusion group. /kg, 30mg/kg, V1) All painful responses were significantly reduced (*p<0.05). When this pain behavior response was confirmed as a change over time, the BOS1 30 mg/kg administration group was also effective in controlling pain at the time of 20 to 35 minutes corresponding to the second pain behavior response. These results showed that BOS1 is effective in the control of acute pain in the temporomandibular joint.

2. SC (subcutaneous) model (facial subcutaneous pain model)

SC (subcutaneous) model (Facial subcutaneous pain model, Won KA, Park SH, Kim BK, Baek KS, Yoon DH, Ahn DK. ; 36(2): 43-50.;Choi HS, Ju JS, Lee HJ, Kim BC, Park JS, Ahn DK.Effects of intracisternal injection of interleukin-6 on nociceptive jaw opening reflex and orofacial formalin test in freely moving rats Using Brain Res Bull 2003; 59(5): 365-370.), the effect of improving the effect on facial subcutaneous pain on BOS1 was tested and the results are shown in FIGS. 3 and 4 below.

When explaining a specific experimental method, the experimental animal was adapted for 10 minutes or more in an experimental plastic container before evaluating the pain response. 5% formalin (50 μl) was injected under the right beard of the experimental animal using an insulin syringe (0.25 m (31 G) m × mm), and the act of rubbing or scratching the face was considered as a pain indicator. The behavioral response was observed for 45 minutes by accumulating in 5 minute increments immediately after the injection, and evaluated by dividing into primary pain response (0 to 10 minutes, first phase) and secondary pain behavior response (11 to 45 minutes, second phase). Did.

Referring to FIGS. 3 and 4 below, in an experiment using an animal (Rat), it is a diagram showing a change in pain behavior response according to the administration of BOS1 in an acute pain model induced with formalin administered to the beard. There was no significant difference between the formalin infusion group, the control group (veh + formalin infusion group), and the drug infusion group when BOS1 was administered, but the secondary pain behavior response was compared to the formalin infusion group (BOS1 15 mg). /kg, 30mg/kg), pain response was significantly reduced (*p<0.05). When this pain behavior response was confirmed as a change over time, when 15 mg/kg of Bos1 was administered, the pain behavior response was effectively reduced at 15 to 35 minutes after drug infusion, and the second pain behavior was also observed in the BOS1 30 mg/kg administration group. It was effective in controlling pain at the time of 15 to 35 minutes corresponding to the reaction. These results showed that BOS1 is effective in controlling acute pain in the face.

3. Comparison of pain model experiment results for complex extracts

Through the experiments of the temporomandibular joint pain model and the subcutaneous pain model for the BOS1, it was confirmed that it is effective in controlling acute pain in the face.

Subsequently, the same experiments were performed for BOS2 to BOS7, and the results were described in terms of BOS1 and exponent in order to perform relative comparison. The effect level of BOS1 was set as an index of 5, and the effect level of BOS2 to 6 was described as an index of 1 to 10, and the higher the score, the better the pain control effect.

BOS1 BOS2 BOS3 BOS4 BOS5 BOS6 BOS7 Temporomandibular joint pain model 5 3 4 6 8 7 6 Subcutaneous pain model of the face 5 3 5 7 9 7 5

Table 2 is a result of comparatively comparing the pain control effects of BOS2 to 7 compared to BOS1. Compared to BOS1, BOS3 and BOS7 showed an equal degree of pain control effect, whereas BOS4 to 6 showed relatively good pain control effect.

In addition, it was confirmed that the BOS2 uses a leaf extract of a mountain tree, and the effect of controlling pain varies depending on the region of the mountain tree.

Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements of those skilled in the art using the basic concepts of the present invention defined in the following claims are also provided. It belongs to the scope of rights.

Claims (6)

Containing Boswellia extract and Seabuckthorn extract
A composition for preventing and improving acute facial pain. According to claim 1,
The Sanja tree extract is selected from the group consisting of a mountain tree trunk, a mountain tree fruit, a mountain tree leaf, a mountain tree root, and mixtures thereof.
A composition for preventing and improving acute facial pain. According to claim 1,
The acute facial pain is selected from the group consisting of afferent blockage pain syndrome, trigeminal neuralgia, burning mouth syndrome, tension headache and acute temporomandibular joint pain.
A composition for preventing and improving acute facial pain. Functional food comprising a composition for preventing and improving acute facial pain according to any one of claims 1 to 3. An external preparation for skin comprising the composition for preventing and improving acute facial pain according to any one of claims 1 to 3. A pharmaceutical product comprising a composition for preventing and improving acute facial pain according to any one of claims 1 to 3.

Images